Geraldine S Pinkus

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article and Find Full Text PDF

March 2019

NK-Cell Enteropathy and Similar Indolent Lymphoproliferative Disorders: A Case Series With Literature Review.

Authors:

Daniel Xia Elizabeth A Morgan David Berger Geraldine S Pinkus Judith A Ferry Lawrence R Zukerberg

Am J Clin Pathol 2019 01;151(1):75-85

The James Homer Wright Pathology Laboratories of the Massachusetts General Hospital, Boston.

View Article and Find Full Text PDF

January 2019

Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.

Authors:

Jeffrey W Craig Michael J Mina Jennifer L Crombie Ann S LaCasce David M Weinstock Geraldine S Pinkus Olga Pozdnyakova

PLoS One 2018 18;13(7):e0199708. Epub 2018 Jul 18.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.

View Article and Find Full Text PDF

December 2018

Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis.

Cell 2018 03 15;173(1):90-103.e19. Epub 2018 Mar 15.

Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article and Find Full Text PDF

March 2018

Loss of Full-Length GATA1 Expression in Megakaryocytes Is a Sensitive and Specific Immunohistochemical Marker for the Diagnosis of Myeloid Proliferative Disorder Related to Down Syndrome.

Authors:

Winston Y Lee Olga K Weinberg Andrew G Evans Geraldine S Pinkus

Am J Clin Pathol 2018 Mar;149(4):300-309

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

View Article and Find Full Text PDF

March 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 04 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article and Find Full Text PDF

April 2018